

electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: January 19, 2001.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 01-2247 Filed 1-19-01; 5:04 pm]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality (AHRQ)

Statement of Organization, Functions, and Delegations of Authority

Part E, Chapter E (Agency for Healthcare Research and Quality), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (61 FR 15955-58, April 10, 1996, most recently amended 65 FR 16395, March 28, 2000) is further amended to reflect recent organizational changes. Specifically, AHRQ is re-titling its Center for Quality Measurement and Improvement as the Center for Quality Improvement and Patient Safety (CQIPS, pronounced "see quips") to reflect the Center's additional functional responsibilities for patient safety. The specific changes are as follows:

1. Under *Section E-10, Organization*, replace "I. Center for Quality Measurement and Improvement" with "I. Center for Quality Improvement and Patient Safety".

2. Under *Section E-20, Functions*, delete the title and statement for the Center for Quality Measurement and Improvement (EL) in its entirety and insert the following:

Center for Quality Improvement and Patient Safety (EL)

Conducts and supports research on the measurement and improvement of the quality of health care and enhancement of patient safety. Specifically, (1) Conducts and supports research, demonstrations, and evaluations of the quality of health care and patient safety; (2) conducts and supports research on the measurement of healthcare quality and promotes the use of these measures; (3) conducts and supports research on effective ways to improve the quality of healthcare and participates in the dissemination of this knowledge; (4) evaluates methods for identifying and preventing medical errors; (5) supports dissemination and communication activities to improve quality of care and patient safety; (6)

designs, conducts, and supports surveys to assess the quality of and satisfaction with health care services and systems; (7) develops and tests measures and methods for evaluating the quality of care and enhancing patient safety; (8) provides technical assistance and gathers information on the use of quality measures, consumer and patient information, and reporting on patient safety and the resulting effects; (9) develops and disseminates an annual report on healthcare quality in general and patient safety specifically; and (10) represents the Agency in meetings with domestic and international experts and organizations concerned with measuring and evaluating the quality of care and enhancing patient safety.

These changes are effective upon date of signature.

Dated: January 17, 2001.

John M. Eisenberg,

Director.

[FR Doc. 01-2064 Filed 1-23-01; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Healthcare Infection Control Practices Advisory Committee: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92-463) of October 6, 1972, that the Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention, of the Department of Health and Human Services, has been renewed for a 2-year period extending through January 19, 2003.

For further information, contact Michele Pearson, M.D., Executive Secretary, Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention, of the Department of Health and Human Services, 1600 Clifton Road, NE, M/S E-69, Atlanta, Georgia 30333, telephone 404/639-6415 or fax 404/639-6459.

The Director, Management and Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: January 18, 2001.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 01-2107 Filed 1-23-01; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (P.L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Advisory Committee on Immunization Practices (ACIP).

Times and Dates: 8:30 a.m.-6:45 p.m., February 21, 2001; 8 a.m.-3:15 p.m., February 22, 2001.

Place: Atlanta Marriott Century Center, 2000 Century Boulevard, N.E., Atlanta, Georgia 30345-3377.

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396b, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

Matters to be Discussed: The agenda will include a discussion on the U.S. influenza surveillance summary; international update and vaccine selection for 2001-2002 influenza season; 2001-2002 control and prevention of influenza recommendations; update on live attenuated influenza vaccine; status report of ACIP statement on prevention of hepatitis B; update on thimerosal and DTaP vaccines; options to transition to thimerosal free DTaP vaccines; polio outbreak in the Dominican Republic; status of outbreak and control measures; policy implications for polio vaccine in the U.S.; stock pile of polio vaccine; update from the Haemophilus influenza b vaccine dose-reduction working group; smallpox vaccine recommendations; recommended use of vaccine for laboratorians working with highly-attenuated and non-attenuated strains of vaccinia virus or other or thopoxviruses; recommended use of vaccine in a bioterrorism event involving smallpox virus; recommendations regarding antiviral alternatives to VIG for treating vaccine adverse reactions; update from the National Center for Infectious Diseases; update from the National Immunization Program; update

from the Food and Drug Administration; update from the National Institutes of Health; update from the Vaccine Injury Compensation Program; update from the National Vaccine Program; Institute of Medicine report on the Immunization Safety Review Committee; review and approval of the general recommendations document; discontinuation of manufacture and marketing of the only licensed cholera vaccine in the U.S. and the only licensed typhoid fever vaccine for children age 6 months–2 years in the U.S.; pertussis among adolescents and adults in the U.S.; data from the APERT trial; update on Td vaccine supply; update on hepatitis A vaccination activities; cost effectiveness of universal childhood vaccination against hepatitis A in states covered by ACIP recommendations; and a StaphVAX phase 3 efficacy trial in end-stage renal disease patients on hemodialysis.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information:

Gloria A. Kovach, Program Analyst, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE., m/s E61, Atlanta, Georgia 30333. Telephone 404/639–8096.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: January 18, 2001.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 01–2109 Filed 1–23–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee, Subcommittee on Future Vaccines, Subcommittee on Immunization Coverage, and Subcommittee on Vaccine Safety and Communication Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub.L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and Dates: 9 a.m.–2:15 p.m., February 13, 2001. 8:30 a.m.–2:45 p.m., February 14, 2001.

Place: Hubert H. Humphrey Building, Room 505A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8:00 a.m. and 8:30 a.m. or 12:30 p.m. and 1:00 p.m. Entrance to the meeting at other times during the day cannot be assured.

Purpose: This committee advises and makes recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.

Matters to be Discussed: Agenda items will include: a report from the National Vaccine Program Office (NVPO) and the Interagency Vaccine Workgroup; a report on the cytomegalovirus vaccine (CMV) meeting; discussions on influenza vaccine supply and delay; pandemic influenza preparedness; NVAC Polio Containment Workgroup report; Vaccine Safety and Communication Subcommittee report; Immunization Coverage Subcommittee report; Future Vaccines Subcommittee report; update from the Office of the Assistant Secretary for Health and Surgeon General; a report on the Global Immunization Initiative; ACCV Annual Report, VRPBC Highlights, and ACIP Highlights; an update on the NVAC Mandatory Immunization Requirements Workgroup and a report of the Introduction of New Vaccines Workgroup.

Name: Subcommittee on Future Vaccines.

Time and Date: 2:15 p.m.–5 p.m., February 13, 2001.

Place: Hubert H. Humphrey Building, Room 305A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee develops policy options and guides national activities that lead to accelerated development, licensure, and the best use of new vaccines in the simplest possible immunization schedules.

Matters to be Discussed: Agenda items will include discussions on new National Institute of Health data on rotavirus and intussusception and future actions regarding CMV based on results of the National Vaccine Advisory Committee sponsored meeting.

Name: Subcommittee on Immunization Coverage.

Time and Date: 2:15 p.m.–5 p.m., February 13, 2001.

Place: Hubert H. Humphrey Building, Room 505A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters to be Discussed: Agenda items will include discussions on adult immunization standards; Pediatric immunization standards; an update on the Introduction of New

Vaccines Workgroup; an update on the Mandatory Immunization Guidelines Workgroup; an update on Immunization Registries Progress Report; discussion of areas of focus for unmet needs funding; an update on the Strategies to Sustain Success Blue Ribbon Panel; and future dates for interim Subcommittee meetings.

Name: Subcommittee on Vaccine Safety and Communication.

Time and Date: 2:15 p.m.–5 p.m., February 13, 2001.

Place: Hubert H. Humphrey Building, Room 325A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee reviews issues relevant to vaccine safety and adverse reactions to vaccines.

Matters to be Discussed: Review of the Executive Summary of the NVAC Risk Communication Workshop; a discussion of the Subcommittee's relationship with IOM; and, discussion of new business.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information:

Gloria Sagar, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D–66, Atlanta, Georgia 30333, telephone 404/687–6672.

Dated: January 18, 2001.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 01–2108 Filed 1–23–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Federal Tax Offset, Administrative Offset, and Passport Denial Programs.

OMB No.: 0970–0161.

Description: The Tax Refund Offset and Administrative Offset Program collects past-due child support by intercepting certain Federal payments, including Federal Tax refunds of parents who have been ordered to pay child support and are behind in paying the debt. The program is a cooperative effort including the Department of Treasury's financial Management Service (FMS), the Federal Office of Child Support Enforcement (OCSE) and State Child Support Enforcement (CSE) agencies. The Passport Denial program reports noncustodial parents who owe arrears above a threshold to Department of State (DOS), which will then deny